References
- Ames F.R., Cridland S.: Anticonvulsant effect of cannabidiol. South African Medical Journal, 1985, 69: 14.
- Andrew J., Hill T.D.M., Walley B.J.: The development of cannabinoid based therapies for epilepsy. In: E. Murillo-Rodríguez Eso, N.A. Darmani, E. Wagner (Eds), Endocannabinoids: molecular, pharmacological, behavioral and clinical features. Oak Park, IL: Bentham Science, 2013: 164–204.
- Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S.: Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia, 2017, 58: 181–221.
- Brodie M.J., Ben-Menachem E.: Cannabinoids for epilepsy: What do we know and where do we go? Epilepsia, 2018, 59: 291–296.
- Brodie M.J., Barry S.J., Bamagous G.A., Norrie J.D., Kwan P.: Patterns of treatment response in newly diagnosed epilepsy. Neurology, 2012, 78: 1548–1554.
- (CDC) Centers for Disease Control and Prevention.: Epilepsy in adults and access to care – United States, 2010. Morbidity and mortality weekly report. MMWR, 2012: 909–913.
- Chiurchiu V., van der Stelt M., Centonze D., Maccarrone M.: The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog. Neurobiol., 2018; 160: 82–100.
- Crippa J.A., Crippa A., Hallak J.E., Martín-Santos R., Zuardi A.W.: 9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Frontiers in pharmacology, 2016, 7: 359.
- Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R. et al.: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980, 21: 175–185.
- Detyniecki K., Hirsch L.J.: Cannabidiol for epilepsy: trying to see through the haze. Lancet Neurol., 2016, 15: 235–237.
- Devinsky O., Patel A.D., Cross J.H., Villanueva V., Wirrell E.C., Privitera M. et al.: Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N. Engl. J. Med., 2018, 378: 1888–1897.
- Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R. et al.: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med., 2017, 376: 2011–2020.
- Devinsky O., Marsh E., Friedman D., Thiele E., Laux L., Sullivan J. et al.: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol., 2015, 15: 270–278.
- Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C. et al.: Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55: 791–802.
- (FDA) U.S. Food and Drug Administration.: FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm (accessed Nov. 12, 2018).
- Friedman D., Cilio M.R., Tilton N.: The effect of epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. Presented at the annual meeting of the American Epilepsy Society, Seattle, December 5–9, 2014. Abstract.
- Gloss D., Vickrey B.: Cannabinoids for epilepsy. Cochrane Database Syst. Rev., 2014, 3: CD009270.
- Gowers W.: Epilepsy and other chronic convulsive disorders. London, Churchill 1881: 223.
- Gupta S.: Weed. In: S. Gupta (ed.). CNN, 2013 (see video promotion for program at http://www.cnn.com/ videos/bestoftv/2013/08/05/gupta-weed-promo.cnn).
- Hall W., Solowij N.: Adverse effects of cannabis. Lancet, 1998, 352: 1611–1616.
- Henderson G.E., Churchill L.R., Davis A.M., Easter M.M., Grady C., Joffe S. et al.: Clinical trials and medical care: defining the therapeutic misconception. PLoS Med., 2007, 4: e324.
- Hill T.D.M., Cascio M.-G., Romano B., Duncan M., Pertwee R.G., Williams C.M. et al.: Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol., 2013, 17: 679–692.
- Iannotti F.A., Di Marzo V., Petrosino S.: Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog. Lipid. Res., 2016, 62: 107–128.
- Iannotti F.A., Hill C.L., Leo A., Alhusaini A., Soubrane C., Mazzarella E. et al.: Nonpsychotropic plant cannabinoids, cannabidavarin (CBDV) and cannabidiol (CBD) activate and desensitise transient receptor potential vanilloid1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem. Neurosci., 2014, 5: 1131–1141.
- Ibeas Bih C., Chen T., Nunn A.V., Bazelot M., Dallas M., Whalley B.J.: Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 2015, 12: 699–730.
- Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G. et al.: Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82: 1556–1563.
- Kwan P., Brodie M.J.: Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342: 314–319.
- Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Hauser A.W., Mathern G. et al.: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51: 1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x.
- Leo A., Russo E., Elia M.: Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol. Res., 2016, 107: 85–92.
- Lorenzetti V., Solowij N., Whittle S., Fornito A., Lubman D.I., Pantelis C. et al.: Gross morphological brain changes with chronic, heavy cannabis use. Br. J. Psychiatry, 2015, 206: 77–78.
- Maccarrone M., Maldonado R., Casas M., Henze T., Centonze D.: Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev. Clin. Pharmacol., 2017, 10: 443–455.
- Maccarrone M., Bab I, Bíró T., Cabral G.A., Dey S.K., Di Marzo V. et al.: Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci., 2015, 36: 277–296.
- Martin P., Consroe P.: Cannabinoid induced behavioral convulsions in rabbits. Science, 1976, 194: 965–967.
- Mathern G.W., Beninsig L., Nehlig A.: Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia’s survey. Epilepsia, 2015, 56: 1–6.
- Mechoulam R., Carlini E.A.: Toward drugs derived from cannabis. Naturwissenschaften, 1978, 65: 174–179.
- Mechoulam R., Shvo Y.: Hashish – I: the structure of cannabidiol. Tetrahedron, 1963, 19: 2073–2078.
- Patsalos P.N., Perucca E.: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol., 2003, 2: 347–356.
- Perucca P., Gilliam F.G.: Adverse effects of antiepileptic drugs. Lancet Neurol., 2012, 11: 792–802.
- Press C.A., Knupp K.G., Chapman K.E.: Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav., 2015, 45: 49–52.
- Radwan M.M., Elsohly M.A., Slade D., Ahmed S.A., Khan I.A., Ross S.A.: Biologically active cannabinoids from high potency Cannabis sativa. Journal of Natural Products, 2009, 72: 906–911.
- Reddy D.S., Golub V.M.: The pharmacological basis of cannabis therapy for epilepsy. J. Pharmacol. Exp. Ther., 2016, 357: 45–55.
- Reynolds J.R.: Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases. John Churchill, London 1861.
- Rheims S., Cucherat M., Arzimanoglou A., Ryvlin P.: Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med., 2008, 5: e166.
- Rosenberg E.C., Tsien R.W., Whalley B., Devinsky O.: Cannabinoids and epilepsy. Neurotherapeutics, 2015, 12: 747–768.
- Santos R.G. dos, Hallak J.E., Leite J.P., Zuardi A.W., Crippa J.A.: Phytocannabinoids and epilepsy. J. Clin. Pharm. Ther., 2015, 40: 135–143.
- Scuderi C., Filippis D.D., Iuvone T., Blasio A., Steardo A., Esposito G.: Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res., 2009, 23: 597–602. doi: 10.1002/ptr.2625.
- Stadnicki S.W., Schaeppi U., Rosenkrantz H., Braude M.C.: Delta 9-tetrahydrocannabinol: subcortical spike bursts and motor manifestations in a Fischer rat treated orally for 109 days. Life Sci., 1974, 14: 463–472.
- Stout S.M., Cimino N.M.: Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev., 2014, 46: 86–95.
- Thiele E.A., Marsh E.D., French J.A., Mazurkiewicz-Beldzinska M., Benbadis S.R., Joshi C. et al.: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWP-CARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391: 1085–1096.
- Trembly B., Sherman M.: Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids. 1990 July 8–11; Kolympari, Crete. International Association for Cannabinoid Medicines, 1990: section 2, p. 5.
- Volkow N.D., Baler R.D., Compton W.M., Weiss S.R.: Adverse health effects of marijuana use. N. Engl. J. Med., 2014, 370: 2219–2227.
- Weimer K., Gulewitsch M.D., Schlarb A.A., Schwille-Kiuntke J., Klosterhalfen S., Enck P.: Placebo effects in children: a review. Pediatr. Res., 2013, 74: 96–102.
- Zendulka O., Dovrtelova G., Noskova K., Turjap M., Šulcová A., Hanuš L. et al.: Cannabinoids and cytochrome P450 interactions. Curr. Drug. Metab., 2016, 17: 206–226.